Michelle Rashford

Direttore Tecnico/Scientifico/R&S presso RACE ONCOLOGY LIMITED

Health Technology

Profilo

Michelle Rashford is currently the Chief Medical Officer at Race Oncology Ltd.
Prior to this, she was the Vice President-Medical Science at Kyowa Kirin, Inc. from 2020 to 2022 and the Senior Vice President-Clinical Science at Hangzhou Adlai Nortye Biopharma Co. Ltd.
from 2018 to 2020.

Posizioni attive di Michelle Rashford

Società	Posizione	Inizio
RACE ONCOLOGY LIMITED	Direttore Tecnico/Scientifico/R&S	01/07/2023

Tutte le posizioni attive di Michelle Rashford

Precedenti posizioni note di Michelle Rashford

Società	Posizione	Fine
Kyowa Kirin, Inc.	Direttore Tecnico/Scientifico/R&S	01/10/2022
Hangzhou Adlai Nortye Biopharma Co. Ltd. Hangzhou Adlai Nortye Biopharma Co. Ltd. BiotechnologyHealth Technology Part of Adlai Nortye Ltd., Hangzhou Adlai Nortye Biopharma Co. Ltd. is a clinical-stage biopharmaceutical company based in Hangzhou, China. Adlai Nortye is developing differentiated, innovative immuno-oncology medicines with a focus on discovering and developing important new treatments for cancer. The Chinese company's mission is to improve patient lives by identifying and developing differentiated innovative medicines that help people live better and longer. The company was founded in 2004 by Yang Lu, Dong Hui Yang, and Yang Lu has been the CEO since then.	Direttore Tecnico/Scientifico/R&S	01/06/2020

Vedi nel dettaglio l'esperienza di Michelle Rashford

Esperienze
Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Vedi nel dettaglio l'esperienza di Michelle Rashford

Relazioni

Relazioni di 1° grado

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Vedi i contatti personali

Società collegate

Società quotate in Borsa	1
RACE ONCOLOGY LIMITED	Health Technology

Aziende private	2
Hangzhou Adlai Nortye Biopharma Co. Ltd. Hangzhou Adlai Nortye Biopharma Co. Ltd. BiotechnologyHealth Technology Part of Adlai Nortye Ltd., Hangzhou Adlai Nortye Biopharma Co. Ltd. is a clinical-stage biopharmaceutical company based in Hangzhou, China. Adlai Nortye is developing differentiated, innovative immuno-oncology medicines with a focus on discovering and developing important new treatments for cancer. The Chinese company's mission is to improve patient lives by identifying and developing differentiated innovative medicines that help people live better and longer. The company was founded in 2004 by Yang Lu, Dong Hui Yang, and Yang Lu has been the CEO since then.	Health Technology
Kyowa Kirin, Inc.